United States Drug Enforcement Administration

CHARLESTON, W.Va. – United States Attorney Moore Capito announced this week that MWI Veterinary Supply Inc. (MWI) has agreed to pay $100,000 to resolve allegations it failed to identify large oxycodone HCL orders from a Putnam County, West Virginia, veterinarian as suspicious or flag them to authorities, resulting in abuse and probable diversion of these drugs.

MWI, also known as MWI Animal Health, is a global distributor of supplies and pharmaceuticals for the veterinary industry based in Boise, Idaho. As a Drug Enforcement Administration (DEA) registrant authorized to distribute controlled substances, MWI is required under the Controlled Substances Act to design and operate a system to identify suspicious orders of controlled substances and to notify the DEA upon discovering such suspicious orders.

Federal investigators found that MWI’s internal Diversion Control Program policies required a suspicious order to be investigated by MWI’s Diversion Control Team, including documentation for the reason the order was flagged. The internal policy identified oxycodone HCL as a substance “especially susceptible to diversion” that required additional scrutiny. MWI’s internal policy noted that its Suspicious Order Monitoring System “will fail if individuals clear orders without adequate investigation.”

The federal investigation found that between March 8, 2018, and July 10, 2023, MWI filled orders totaling 14,200 dosage units of hydrocodone/acetaminophen at 10 milligrams each, 800 dosage units of oxycodone HCL at 10 milligrams each, and 600 dosage units of oxycodone HCL at 5 milligrams each for Dr. Clara Ann Mason, the Putnam County veterinarian. 

These orders were determined to be unusual for a veterinary practice, and amount to more than 16 times the national average for medical practitioners. For the years 2021, 2022, and 2023, Mason ordered substantially more hydrocodone/acetaminophen from MWI than any other individual customer. Mason accounted for all oxycodone HCL dosage units filled by MWI for West Virginia veterinarians in 2022 and 2023.

On September 13, 2022, MWI’s Suspicious Order Monitoring System flagged Mason’s order that day for 300 dosage units of oxycodone HCL at 10 milligrams each. Federal investigators determined than an MWI representative opened the suspicious order for review and released it the next day without substantial investigation. MWI filled nine subsequent orders for oxycodone HCL from Mason, including one for approximately 1,300 pills, without questioning Mason or doing further due diligence.

“DEA registrants like MWI are obligated to uphold the stringent reporting requirements outlined in the Controlled Substances Act; a failure to do so can result in the diversion of medications that have a high potential for abuse, and endanger our communities,” said Jim Scott, Special Agent in Charge of DEA’s Louisville Division, which serves Kentucky, Tennessee and West Virginia.  “Hopefully, today’s settlement will serve as a costly reminder that compels MWI to take the threat of drug diversion seriously.”

“The authority to distribute controlled substance requires complete adherence to the law and mandated internal policies to protect our communities against the consequences of diversion and abuse,” Capito said. “This settlement agreement is the result of outstanding work by the Drug Enforcement Administration, our office’s Affirmative Civil Enforcement and Health Care Fraud Investigative Specialist Tyler E. Japhet, and Assistant United States Attorney Gregory P. Neil.” 

Capito’s office secured a $956,709 default judgment against Mason on July 31, 2025. United States District Judge Robert C. Chambers ordered Mason to pay the maximum civil penalties, concluding that she ordered thousands of doses of opioids and other drugs, failed to keep these drugs secured, failed to keep track of these drugs, and apparently fabricated records to cover her failures.

###